Inici › Càncer de bufeta › Texas › Houston
Assaigs clínics de Càncer de bufeta a Houston, TX
31 estudis de Càncer de bufeta busquen participants en centres de Houston i voltants (en un radi d'uns 30 milles). Obre un estudi per veure qui hi pot participar i com contactar amb l'equip.
Text oficial de l'estudi (anglès)
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
ReclutantFase 1
- University of Texas MD Anderson Cancer Center, Houston
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
ReclutantEstudi observacionalVoluntaris sans benvinguts
- UT MD Anderson Cancer Center, Houston
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
ReclutantFase 2
- The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
ReclutantFase 2
- The University of Texas MD Anderson Cancer Center, Houston
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
ReclutantFase 1
- University of Texas MD Anderson Cancer Center, Houston
- The University of Texas, MD Anderson Cancer Center - West Houston, Houston
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
ReclutantFase 2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
ReclutantFase 1/2
- Texas Oncology - Gulf Coast, Houston
- Texas Oncology - Gulf Coast, Houston
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
ReclutantFase 1
- MD Anderson, Houston
- NEXT Oncology Houston, Houston
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
ReclutantFase 3
- University of Texas MD Anderson Cancer Center, Houston
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
ReclutantFase 1/2
- MD Anderson Cancer Center, Houston
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
ReclutantFase 1
- MD Anderson Cancer Center, Houston
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
ReclutantFase 2
- Houston Methodist, Houston
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
ReclutantFase 2
- Houston Metro Urology, Houston
- Houston Methodist Hospital, Houston
Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer
ReclutantFase 3
- Houston Metro Urology, Houston
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
ReclutantFase 1
- MD Anderson Cancer Center, Houston
Measuring Surgical Recovery After Radical Cystectomy
ReclutantEstudi observacional
- University of Texas MD Anderson Cancer Center, Houston
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
ReclutantFase 3
- M D Anderson Cancer Center, Houston
- MD Anderson West Houston, Houston
A Study of MGC026 in Participants With Advanced Solid Tumors
ReclutantFase 1
- The University of Texas MD Anderson Cancer Center, Houston
- University of Texas Health Science Center at Houston, Houston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
ReclutantFase 1/2
- The University of Texas, MD Anderson Cancer Center, Houston
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
ReclutantFase 1/2
- Houston Metro Urology, Houston
- Houston Methodist Hospital - Department of Urology, Houston
- University of Texas - MD Anderson Cancer Center, Houston
IDOV-Immune for Advanced Solid Tumors
ReclutantFase 1
- MD Anderson Cancer Center, Houston
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
ReclutantFase 2
- University of Texas MD Anderson Cancer Center, Houston
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
ReclutantFase 2
- The University of Texas MD Anderson Cancer Center, Houston
A First in Human Study of PLT012 in Participants With Solid Tumor Cancers
ReclutantFase 1
- MD Anderson Cancer Center, Houston
- NEXT Houston, Houston
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
ReclutantFase 1
- Oncology Consultants, PA, Houston
- Oncology Consultants, PA., Houston
- The University of Texas M.D. Anderson Cancer Center, Houston
Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery
ReclutantFase 2
- Houston Methodist Neal Cancer Center, Houston
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
ReclutantEstudi observacional
- Md Anderson Cancer Center, Houston
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
ReclutantFase 1
- MD Anderson Cancer Center, Houston
Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
ReclutantFase 1
- Baylor St. Luke's Medical Center, Houston
Blue Light Cystoscopy With Cysview® Registry
ReclutantEstudi observacional
- Michael E. DeBakey VA Medical Center, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
ReclutantEstudi observacional
- Massive Bio SYNERGY-AI site, Houston
Assaigs de Càncer de bufeta en altres ciutats
- New York City, NY35 estudis
- Nashville, TN31 estudis
- Dallas, TX27 estudis
- Boston, MA26 estudis
- Washington, DC26 estudis
- Los Angeles, CA24 estudis
- Baltimore, MD24 estudis
- St. Louis, MO22 estudis
- Philadelphia, PA21 estudis
- Seattle, WA21 estudis
- Edison, NJ21 estudis
- Chicago, IL21 estudis
Altres estudis a Houston
- Càncer de pulmó de cèl·lules no petites145 estudis
- Càncer de mama126 estudis
- Càncer (tots els tipus)121 estudis
- Càncer metastàtic104 estudis
- Càncer colorrectal102 estudis
- Càncer d'ovari89 estudis
- Leucèmia mieloide aguda85 estudis
- Càncer de pulmó78 estudis
- Càncer de pròstata76 estudis
- Càncer d'endometri68 estudis
- Càncer de pàncrees61 estudis
- Melanoma59 estudis
De ClinicalTrials.gov, dades recuperades el 5 d’oct. 2026. Cada estudi estableix els seus propis criteris d'elegibilitat; l'equip de l'estudi decideix qui hi pot participar.